RPTX241220C5000
- 0.05
- -0.35-87.50%
Repare Therapeutics Newsroom
Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX) and Centene (CNC)
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
LifeSci Capital Downgrades Repare Therapeutics(RPTX.US) to Hold Rating
Repare Therapeutics Is Maintained at Buy by Stifel
Repare Therapeutics Analyst Ratings
LifeSci Capital Downgrades Repare Therapeutics (RPTX) to a Hold
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Cuts Target Price to $4
TD Cowen Maintains Repare Therapeutics(RPTX.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for Repare Therapeutics (RPTX)
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Morgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)
TD Cowen Maintains Repare Therapeutics(RPTX.US) With Buy Rating
Repare Therapeutics Analyst Ratings
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10
Repare Therapeutics: Strong Financial Health and Promising Data Catalysts Justify Buy Rating With $10 Price Target
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $8
Repare Therapeutics Analyst Ratings
H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10
Repare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical Outcomes